In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Related Pages

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

Combination Therapy Shows Promise for Treating Advanced Breast Cancer
(Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.

New Therapies Offer Valuable Options for Patients with Melanoma
(Posted: 07/19/2011, Updated: 12/07/2011) - Two phase III clinical trials of new therapies for patients with metastatic melanoma presented in June at the 2011 ASCO conference confirmed that the molecularly targeted agent vemurafenib and the immunotherapy agent ipilimumab (Yervoy™) offer valuable new options for a disease in which effective treatments have been lacking.

Second HPV Vaccine Shows Early Positive Results
(Posted: 07/17/2007, Updated: 12/02/2011) - The vaccine Cervarix® was 90 percent effective against two types of human papillomavirus (HPV) that can cause cervical cancer, according to the June 30, 2007, Lancet.

Study Confirms Letrozole Prevents More Breast Cancer Recurrences than Tamoxifen
(Posted: 12/02/2011) - After a median of 8 years of follow-up from a large randomized trial, women with estrogen-receptor positive breast cancer who received 5 years of treatment with letrozole were less likely to have their cancer recur or to die during follow-up than women who had 5 years of treatment with tamoxifen.

Study Suggests Smaller Melanoma Excision Margins May Be Option for Some Patients
(Posted: 12/02/2011) - A randomized controlled trial of patients with stage IIA–C cutaneous melanoma thicker than 2-mm found that a 2-cm surgical resection margin is sufficient and is as safe for patients as a 4-cm margin in terms of overall survival, according to a report published online October 21 in The Lancet.

< Previous  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  Next >